Read by QxMD icon Read


Jae Seung Jeong, Woon-Kyu Lee, Yeon Sung Moon, Na Rae Kim
PURPOSE: This study aims to evaluate early changes in retinal structure and BMP2 expression in the retina and crystalline lens by comparing streptozotocin-induced diabetic pigs and normal control group pigs. METHODS: Five eye samples from five diabetic Micro-pigs (Medikinetics, Pyeongtaek, Korea) and five eye samples from five control pigs bred in a specific pathogen-free area were used. Diabetes was developed through intravenous injection of nicotinamide and streptozotocin, and the average fasting glucose level was maintained at 250 mg/dL or higher for 16 weeks...
September 2017: Laboratory Animal Research
Niels Peter Nielsen, Elisabeth H Wiig, Svante Bäck, Jan Gustafsson
BACKGROUND: Treatment responses to methylphenidate by adults with ADHD are generally monitored against DSM-IV/DSM-V symptomatology, rating scales or interviews during reviews. AIMS: To evaluate the use of single- and dual-dimension processing-speed and efficiency measures to monitor the effects of pharmacological treatment with methylphenidate after a short period off medication. METHODS: A Quick Test of Cognitive Speed (AQT) monitored the effects of immediate-release methylphenidate in 40 previously diagnosed and medicated adults with ADHD...
May 2017: Nordic Journal of Psychiatry
Xiaoxia Yang, John Duan, Jeffrey Fisher
A previously presented physiologically-based pharmacokinetic model for immediate release (IR) methylphenidate (MPH) was extended to characterize the pharmacokinetic behaviors of oral extended release (ER) MPH formulations in adults for the first time. Information on the anatomy and physiology of the gastrointestinal (GI) tract, together with the biopharmaceutical properties of MPH, was integrated into the original model, with model parameters representing hepatic metabolism and intestinal non-specific loss recalibrated against in vitro and in vivo kinetic data sets with IR MPH...
2016: PloS One
Jurjen van der Schans, Nikos Kotsopoulos, Pieter J Hoekstra, Eelko Hak, Maarten J Postma
BACKGROUND: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder in children and adolescents. Immediate-release methylphenidate (IR-MPH) is the medical treatment of first choice. The necessity to use several IR-MPH tablets per day and associated potential social stigma at school often leads to reduced compliance, sub-optimal treatment, and therefore economic loss. Replacement of IR-MPH with a single-dose extended release (ER-MPH) formulation may improve drug response and economic efficiency...
2015: PloS One
David Coghill, Tobias Banaschewski, Alessandro Zuddas, Antonio Pelaz, Antonella Gagliano, Manfred Doepfner
BACKGROUND: The stimulant methylphenidate (MPH) has been a mainstay of treatment for attention-deficit/hyperactivity disorder (ADHD) for many years. Owing to the short half-life and the issues associated with multiple daily dosing of immediate-release MPH formulations, a new generation of long-acting MPH formulations has emerged. Direct head-to-head studies of these long-acting MPH formulations are important to facilitate an evaluation of their comparative pharmacokinetics and efficacy; however, to date, relatively few head-to-head studies have been performed...
September 27, 2013: BMC Psychiatry
Esther Sobanski, Manfred Döpfner, Claudia Ose, Roland Fischer
This multi-centre, open-label, non-interventional study evaluates effectiveness, safety and adherence to treatment of a specific extended-release methylphenidate with a 50 % immediate and a 50 % extended-release component (Medikinet(®) retard) in the clinical routine treatment of 381 adolescents with ADHD and a mean age of 14.0 ± 1.9 years. ADHD and associated psychiatric symptoms, medication status and dosage frequency, treatment adherence and adverse events were assessed at baseline and after a median treatment length with Medikinet(®) retard of 70 days...
December 2013: Attention Deficit and Hyperactivity Disorders
Rafael Maldonado
INTRODUCTION: Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder of which the main features are inattention, hyperactivity and impulsivity. Methylphenidate (MPH) is the mainstay of treatment, but its short duration of action and consequent need for multiple administrations has been problematic for children attending school. Extended-release (ER) formulations have been developed to help overcome the drawbacks associated with immediate-release (IR) preparations...
August 2013: Expert Opinion on Drug Metabolism & Toxicology
Dieter Breuer, Anja Görtz-Dorten, Aribert Rothenberger, Manfred Döpfner
DAYAS is a new two-part rating scale that assesses: (1) ADHD and ODD symptoms (externalising symptom ratings) and (2) symptomatology potentially related to ADHD medication (potentially medication-related symptoms) in real-world settings at different time periods throughout a normal school day. Data from a proof-of-concept study and two observational trials (Medikinet(®) retard [methylphenidate] and the Equasym XL(®) [methylphenidate] OBSEER study) evaluated: (1) validity of weekly externalising symptom ratings using DAYAS, in place of daily ratings; (2) reliability and internal consistency of DAYAS ratings for externalising symptoms and potentially medication-related symptoms; and (3) convergent and divergent validity of the externalising symptom ratings with existing validated scales...
October 2011: European Child & Adolescent Psychiatry
Manfred Döpfner, Claudia Ose, Roland Fischer, Richard Ammer, André Scherag
OBJECTIVE: The comparison of the efficacy of Medikinet(®) retard and Concerta(®) trial was a multisite, randomized, double-blind, crossover trial that aimed at comparing the effects of two different modified release methylphenidate preparations (Medikinet retard: 50% immediate release (IR); Concerta: 22% IR) in a natural setting across the day in 113 randomized children and adolescents with attention-deficit/hyperactivity disorder (age range 6-16 years). The duration of the study per patient was 3 weeks...
October 2011: Journal of Child and Adolescent Psychopharmacology
Christian Wolff, Adam Alfred, Anton Lindermüller, Klaus Rettig, Fritz Mattejat, Martin Gerwe, Lara Slawik, Barbara Schäuble
BACKGROUND: To explore the clinical outcomes of children/adolescents with ADHD who transitioned from extended-release methylphenidate (ER MPH, Medikinet Retard) to osmotic release oral system (OROS) MPH (Concerta). Medikinet Retard is a registered trade name of Medice, Bad Iserlohn, Germany. Concerta is a registered trade name of Janssen-Cilag GmbH, Neuss, Germany. METHODS: This prospective, non-interventional study included patients aged 6 to 18 years with a confirmed diagnosis of ADHD who experienced insufficient clinical response and/or poor tolerability on ER MPH...
2011: Current Medical Research and Opinion
Eberhard Schulz, Christian Fleischhaker, Klaus Hennighausen, Philip Heiser, Klaus-Uwe Oehler, Martin Linder, Frank Haessler, Michael Huss, Andreas Warnke, Martin Schmidt, Michael Schulte-Markworth, Christian Sieder, Jan Klatt, Ferenc Tracik
OBJECTIVES: The primary objective of this study was to demonstrate efficacy of Ritalin(®) LA 20 mg by showing superiority to placebo and noninferiority to Medikinet(®) Retard in a laboratory classroom setting. Secondary objectives included safety/tolerability and further efficacy parameters. METHODS: A total of 147 children with attention-deficit/hyperactivity disorder (ADHD) diagnosed by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) and aged 6-14 (81% males) and known to be methylphenidate (MPH) responders were enrolled in this multicenter, double-blind, randomized, placebo/active-controlled, three-period (7 days each) crossover study...
October 2010: Journal of Child and Adolescent Psychopharmacology
Alberto Fernández-Jaén, Daniel Martín Fernández-Mayoralas, Alexandra Pardos, Beatriz Calleja-Pérez, Nuria Muñoz Jareño
INTRODUCTION: The objective of the study was to assess the efficacy of extended-release methylphenidate (Mph-ER) (Medikinet; MEDICE Arzneimittel Pütter GmbH & Co KG, Iserlohn, Germany) in the pediatric population with attention deficit/hyperactivity disorder (ADHD); a parallel analysis of the validity of various tools for monitoring short-term clinical response to treatment was made. METHODS: This was a retrospective analysis of 94 children with ADHD who received treatment with Mph-ER...
December 2009: Advances in Therapy
H Schütz, R Fischer, M Grossmann, D Mazur, H J Leis, R Ammer
OBJECTIVE: To assess bioequivalence between Equasym Retard and Medikinet retard containing 20 mg methylphenidate (MPH) hydrochloride in a fed state. MATERIALS: Equasym Retard 20 mg capsules (UCB, Monheim, Germany) and Medikinet retard 20 mg capsules (Medice, Iserlohn, Germany). METHODS: This was an open, single-center, randomized, 2-period, 2-sequence, balanced cross-over study with a wash-out period of 1 week between administrations in 14 healthy male and female volunteers, aged 18 - 45 years...
December 2009: International Journal of Clinical Pharmacology and Therapeutics
Robert Janknegt, Adrianne Faber, Rob Rodrigues Pereira, Luuk J Kalverdijk
The purpose of this review is to facilitate discussion on drug selection for the treatment of ADHD by using only clinically relevant selection criteria and providing an up-to-date overview. The InforMatrix method was used to select drugs to treat attention deficit hyperactivity disorder (ADHD). The following selection criteria were applied: clinical efficacy, safety, tolerability, ease of use, applicability, and cost. The drugs approved for ADHD in the Netherlands were included in the analysis, namely: atomoxetine, immediate-release methylphenidate, and various formulations of slow-release methylphenidate (Concerta, Equasym and Medikinet)...
April 2009: Expert Opinion on Pharmacotherapy
F Haessler, F Tracik, H Dietrich, H Stammer, J Klatt
OBJECTIVES: Primary objective was to investigate bioequivalence of Ritalin LA(R); 40 mg compared to Medikinet retard 40 mg in healthy male volunteers under fasted and fed conditions. Secondary objectives included assessment of tolerability and determination of further pharmacokinetic parameters. The difference between the kinetic profiles of Ritalin LA(R) and Medikinet retard with respect to breakfast intake was additionally explored. METHODS: 28 subjects were randomized in this open-label, four-treatment, cross-over-design study...
September 2008: International Journal of Clinical Pharmacology and Therapeutics
Thomas Jans, Alexandra Philipsen, Erika Graf, Christina Schwenck, Manfred Gerlach, Andreas Warnke, Studiengruppe Aimac
Given its high heritability, ADHD frequently affects both children and their parents. In addition to co-morbid psychiatric disorders, adults with ADHD often complain of psychosocial difficulties, including family conflicts and poor parenting skills. Inconsistent childrearing practices and parent-child conflicts negatively affect the course of ADHD in children. Moreover, in the case of parental ADHD, the efficacy of parent training as part of the treatment for the child's ADHD seems to be reduced. This article presents a review of the impact of ADHD in mothers on the treatment of their ADHD children...
September 2008: Zeitschrift Für Kinder- und Jugendpsychiatrie und Psychotherapie
Judith Sinzig, Manfred Döpfner, G Lehmkuhl, H Uebel, K Schmeck, F Poustka, W D Gerber, M Günter, U Knölker, M Gehrke, F Hässler, F Resch, M Brünger, C Ose, R Fischer
INTRODUCTION: Aggression is frequently observed in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). The aim of this study was to assess the efficacy with regard to oppositional and aggressive behavior of a new long-acting methylphenidate preparation (Medikinet retard, MPH-MR), with equal portions of the immediate-release and the sustained-release active substance, and especially to look at correlations between either teacher or parent assessment of aggression and ADHD sub-symptomatology...
August 2007: Journal of Child and Adolescent Psychopharmacology
R Fischer, H Schütz, M Grossmann, H J Leis, R Ammer
OBJECTIVE: To assess bioequivalence between an intact capsule and the content of a capsule sprinkled on applesauce. MATERIALS: Medikinet retard 20 mg capsules were obtained from Medice (Iserlohn, Germany). METHODS: This was a single-center, completely randomized, open, 2-period, 2-sequence, balanced crossover study with a washout period of 1 week between administrations, in 12 healthy male and female subjects, aged 18-45 years. Blood samples were collected over 24 hours and methylphenidate plasma concentration-time data were used to calculate pharmacokinetic parameters for both administrations...
March 2006: International Journal of Clinical Pharmacology and Therapeutics
Judith K Sinzig, Manfred Döpfner, Julia Plück, Tobias Banaschewski, Ulrich Stephani, Gerd Lehmkuhl, Aribert Rothenberger et al.
OBJECTIVES: In order to treat children with Attention-deficit/Hyperactivity Disorder (ADHD) with a once-a-day stimulant several galenic approaches have been tried. The long acting methylphenidate (MPH, Medikinet-Retard) is a preparation with a two-step dynamic to release MPH (step one: acute; step two: prolonged). The efficacy of Medikinet-Retard, a new long-acting methylphenidate preparation, is analyzed based on the assessment of parents in the afternoon. METHODS: In a multicenter drug treatment study (placebo controlled, randomized, double-blind) 85 children (normal intelligence, age 6 to 16 years, diagnosis of ADHD according to DSM-IV) were investigated over 4 weeks with weekly visits...
November 2004: Zeitschrift Für Kinder- und Jugendpsychiatrie und Psychotherapie
Manfred Döpfner, Wolff Dieter Gerber, Tobias Banaschewski, Dieter Breuer, Franz Joseph Freisleder, Gabi Gerber-von Müller, Michael Günter, Frank Hässler, Claudia Ose, Aribert Rothenberger, Klaus Schmeck, Judith Sinzig, Christina Stadler, Henrik Uebel, Gerd Lehmkuhl
BACKGROUND: Given the dosing limitations of methylphenidate short-acting preparations in treating ADHD, galenics with longer release of the substance were developed mainly to avoid drug intake during school hours. OBJECTIVES: This investigation was conducted to assess the efficacy and the duration of action of a new extended-release formulation of methylphenidate (Medikinet retard) as a once-daily treatment for children with attention-deficit hyperactivity disorder (ADHD)...
2004: European Child & Adolescent Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"